08.06.2020 STRATEC SE  DE000STRA555

DGAP-News: STRATEC'S ANNUAL GENERAL MEETING APPROVES DISTRIBUTION OF A DIVIDEND OF € 0.84 PER SHARE


 

DGAP-News: STRATEC SE / Key word(s): AGM/EGM
STRATEC'S ANNUAL GENERAL MEETING APPROVES DISTRIBUTION OF A DIVIDEND OF € 0.84 PER SHARE

08.06.2020 / 15:52
The issuer is solely responsible for the content of this announcement.


STRATEC'S ANNUAL GENERAL MEETING APPROVES DISTRIBUTION OF A DIVIDEND OF € 0.84 PER SHARE

Birkenfeld, June 8, 2020

At today's Annual General Meeting of STRATEC SE (Frankfurt: SBS; Prime Standard, SDAX) which, due to the COVID-19 pandemic, was held on a virtual basis for the first time, the company's shareholders approved all agenda items submitted for resolution with clear majorities. Overall, 81.8% of the company's share capital was represented at the virtual Annual General Meeting.

As proposed, STRATEC will be distributing a dividend of € 0.84 per share to its shareholders for the past 2019 financial year (previous year: € 0.82). The distribution total amounts to € 10.1 million and will be paid out to shareholders via their depositing banks on June 12, 2020. This represents the sixteenth consecutive increase in the dividend since payment of the first dividend in 2004.

Shareholders also approved the actions of the Board of Management and the Supervisory Board and elected Ebner Stolz GmbH & Co. KG, Stuttgart, as auditor for the 2020 financial year. The Annual General Meeting also renewed its approval for authorized and conditional capital, as well as the authorization to acquire and dispose of treasury stock.

Rather than holding a general debate, shareholders had the opportunity to submit questions in advance of the Annual General Meeting. All questions were addressed during the meeting.

Further information about the Annual General Meeting can be found at www.stratec.com/agm, where details of voting results have also been published.

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain - from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler | Investor Relations & Corporate Communications
Tel: +49 7082 7916-6515
Fax: +49 7082 7916-9190
[email protected]
www.stratec.com



08.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: [email protected]
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1064815

 
End of News DGAP News Service

1064815  08.06.2020 

fncls.ssp?fn=show_t_gif&application_id=1064815&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 146,89 184,91 209,76 187,82 214,16 250,10 281,00
EBITDA1,2 33,11 35,41 47,33 35,53 35,60 56,27 79,00
EBITDA-Marge3 22,54 19,15 22,56 18,92 16,62 22,50 28,11
EBIT1,4 26,88 24,20 28,84 15,01 17,19 33,68 50,50
EBIT-Marge5 18,30 13,09 13,75 7,99 8,03 13,47 17,97
Jahresüberschuss1 22,08 25,38 25,64 8,97 14,41 25,18 33,90
Netto-Marge6 15,03 13,73 12,22 4,78 6,73 10,07 12,06
Cashflow1,7 26,03 16,26 29,98 11,95 21,26 31,85 40,00
Ergebnis je Aktie8 1,85 1,63 2,22 0,75 1,20 2,07 2,90
Dividende8 0,75 0,77 0,80 0,82 0,84 0,90 1,05
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ebner Stolz

INVESTOR-INFORMATIONEN
©boersengefluester.de
Stratec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
STRA55 132,200 Halten 1.601,52
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
37,77 31,72 1,18 80,81
KBV KCV KUV EV/EBITDA
9,91 50,28 6,40 29,89
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
Hauptversammlung
0,84 0,90 0,68 20.05.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
07.05.2021 06.08.2021 11.11.2021 31.03.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
13,98% 11,50% 7,65% 36,01%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu STRATEC SE  ISIN: DE000STRA555 können Sie bei DGAP abrufen

Medtech , STRA55 , SBS , XETR:SBS